HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Essential mixed cryoglobulinemia — Clinical Guidelines

Overview

Essential mixed cryoglobulinemia is a systemic vasculitis characterized by the presence of circulating immune complexes composed of polyclonal immunoglobulins and monoclonal components, leading to multi-organ involvement including neuropathy, nephropathy, and vasculitic complications 2 3 4.

Diagnosis

Presence of mixed cryoglobulins (type II or III) in serum 1 3

Clinical manifestations indicative of vasculitis affecting multiple organs (e.g., neuropathy, renal involvement) 2 3 4

Biopsy evidence of vasculitis with vessel wall changes in affected tissues 3

Nerve conduction studies may show axonal sensorimotor polyneuropathy 3

Management

First-line treatments: Rituximab for immune complex reduction 1

Adjunctive therapies: Corticosteroids for acute exacerbations 2

Supportive care: Management of specific organ involvement (e.g., dialysis for renal failure, anticoagulation for thrombotic events) 4

Special Populations

Comorbidities: Careful monitoring and management of organ-specific complications (e.g., nephropathy, neuropathy) in patients with existing comorbidities 2 3 4

No specific data: Limited information on pediatrics, pregnancy, or elderly populations 1 2 3 4

Key Recommendations

Monitor for development of cold agglutinin disease post-rituximab treatment, especially for signs of hemolysis and microvascular complications (Evidence: Weak) 1

Consider vasculitic involvement in peripheral and central nervous system symptoms, warranting nerve and brain biopsies for definitive diagnosis (Evidence: Moderate) 2 3

Evaluate for and manage cryoglobulinemic nephropathy with renal biopsy to confirm mesangiocapillary glomerulonephritis and associated vascular changes (Evidence: Weak) 4

References

1 Ruch J, McMahon B, Ramsey G, Kwaan HC. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with rituximab. American journal of hematology 2009. link 2 Serena M, Biscaro R, Moretto G, Recchia E. Peripheral and central nervous system involvement in essential mixed cryoglobulinemia: a case report. Clinical neuropathology 1991. link 3 Nemni R, Corbo M, Fazio R, Quattrini A, Comi G, Canal N. Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain : a journal of neurology 1988. link 4 Koelz AM, Bourke E. Cryoglobulinaemic nephropathy with papillary necrosis. Nephron 1977. link

Essential mixed cryoglobulinemia